I

Innate Pharma SA

D
IPHA
USD
-0.05
(-2.3041%)
Market Closed
97.000
Volume
-0.67
EPS
-
Div Yield
-4.537507
P/E
171,615,657.84
Market Cap
Today
-2.3041%
1 Week
-10.549%
1 Month
-4.933%
6 Months
-12.397%
12 Months
-27.768%
Year To Date
-24.286%
All Time
-64.489%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
I
INO
-0.09
(-1.3294%)
USD
V
VBIV
(%)
USD
MRNA
MRNA
-1.79
(-2.5637%)
USD
N
NVAX
-0.01
(-0.0796%)
USD
I
IBIO
0.072
(4.0223%)
USD
A
ALT
0.15
(2.0188%)
USD
V
VXRT
-0.0008
(-0.0886%)
USD
B
BNTX
-3
(-2.5972%)
USD
PFE
PFE
-0.09
(-0.3025%)
USD
MRK
MRK
-1.44
(-1.2137%)
USD

Title:
Innate Pharma SA

Sector:
Healthcare
Industry:
Biotechnology
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
Do you need help or have a question?
Contact Us